Michael Allison

14.9k total citations · 5 hit papers
108 papers, 6.4k citations indexed

About

Michael Allison is a scholar working on Epidemiology, Hepatology and Surgery. According to data from OpenAlex, Michael Allison has authored 108 papers receiving a total of 6.4k indexed citations (citations by other indexed papers that have themselves been cited), including 52 papers in Epidemiology, 40 papers in Hepatology and 26 papers in Surgery. Recurrent topics in Michael Allison's work include Liver Disease Diagnosis and Treatment (48 papers), Liver Disease and Transplantation (32 papers) and Organ Transplantation Techniques and Outcomes (20 papers). Michael Allison is often cited by papers focused on Liver Disease Diagnosis and Treatment (48 papers), Liver Disease and Transplantation (32 papers) and Organ Transplantation Techniques and Outcomes (20 papers). Michael Allison collaborates with scholars based in United Kingdom, United States and Italy. Michael Allison's co-authors include Douglas T. Fearon, Christopher C. Goodnow, Paul W. Dempsey, Quentin M. Anstee, Graeme Alexander, Tim Wreghitt, Chris Palmer, Antonio Vidal‐Puig, Michèle Vacca and Emmanuel Tsochatzis and has published in prestigious journals such as Nature, Science and The Lancet.

In The Last Decade

Michael Allison

104 papers receiving 6.2k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

C3d of Complement as a Molecular Adjuvant: Bridging Innate and Acquired Immunity

1996 941 citations Michael Allison et al. profile →
Accuracy of FibroScan Controlled Attenuation Parameter and Liver Stiffness Measurement in Assessing Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease

2019 930 citations Peter Eddowes, M. Sasso et al. Gastroenterology profile →
TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease

2014 454 citations Stuart McPherson, Michael Allison et al. profile →
Adipose Tissue-Liver Cross Talk in the Control of Whole-Body Metabolism: Implications in Nonalcoholic Fatty Liver Disease

2020 237 citations Vian Azzu, Michèle Vacca et al. Gastroenterology profile →
Acquisition of epithelial plasticity in human chronic liver disease

2024 44 citations Christopher Gribben, Vasileios Galanakis et al. Nature profile →

Peers

Countries citing papers authored by Michael Allison

Since Specialization

Citations

This map shows the geographic impact of Michael Allison's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Allison with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Allison more than expected).

Fields of papers citing papers by Michael Allison

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael Allison. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Allison. The network helps show where Michael Allison may publish in the future.

Co-authorship network of co-authors of Michael Allison

This figure shows the co-authorship network connecting the top 25 collaborators of Michael Allison. A scholar is included among the top collaborators of Michael Allison based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael Allison. Michael Allison is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Defining Risk in Alcohol-Associated Liver Disease Using the Model for End-Stage Liver Disease 2025 ·The American Journal of Gastroenterology ·Richard Parker, Guruprasad P. Aithal, Michael Allison, Mayur Brahmania, Ewan Forrest, Hannes Hagström, Brian T. Lee, (unknown), Anne McCune, Timothy R. Morgan, (unknown), Steven Masson, Neil Rajoriya, Devanshi Seth, Ken Liu, (unknown), Esperance Schaefer, Jay Luther, Russell P. Goodman, Ian Rowe, (unknown)	0
2	Acquisition of epithelial plasticity in human chronic liver disease breakdown → 2024 ·Nature ·Christopher Gribben, Vasileios Galanakis, Alexander Calderwood, Eleanor C Williams, (unknown), (unknown), Carla Frau, Tobias Puengel, Adrien Guillot, Foad J. Rouhani, Krishnaa T. Mahbubani, Edmund Godfrey, Susan E. Davies, Emmanouil Athanasiadis, Kourosh Saeb‐Parsy, Frank Tacke, Michael Allison, Irina Mohorianu, Ludovic Vallier	44
3	Nutritional Intake after Liver Transplant: Systematic Review and Meta-Analysis 2023 ·Nutrients ·(unknown), Angela Madden, (unknown), Fumiaki Imamura, Danielle Jones, (unknown), Hong Kai Lim, (unknown), Kirsten L. Rennie, Linda M. Oude Griep, Michael Allison, Simon J. Griffin	2
4	Extra‐hepatic morbidity and mortality in alcohol‐related liver disease: Systematic review and meta‐analysis 2023 ·Liver International ·(unknown), Guruprasad P. Aithal, Michael Allison, Mayur Brahmania, Ewan Forrest, Hannes Hagström, Stine Johansen, Aleksander Krag, Alisa Likhitsup, Steven Masson, Anne McCune, Neil Rajoriya, Maja Thiele, Ian Rowe, Richard Parker	16
5	Non-alcoholic fatty liver disease is characterised by a reduced polyunsaturated fatty acid transport via free fatty acids and high-density lipoproteins (HDL) 2023 ·Molecular Metabolism ·Gabriele Mocciaro, Michael Allison, Benjamin Jenkins, Vian Azzu, Isabel Huang‐Doran, Luis V. Herrera‐Marcos, Zoe Hall, Antonio Murgia, (unknown), Mattia Frontini, Antonio Vidal‐Puig, Albert Koulman, Julian L. Griffin, Michèle Vacca	33
6	Breath Biopsy^® to Identify Exhaled Volatile Organic Compounds Biomarkers for Liver Cirrhosis Detection 2023 ·Journal of Clinical and Translational Hepatology ·Giuseppe Ferrandino, (unknown), Antonio Murgia, (unknown), Ahmed Tawfike, Rob Smith, Irene Debiram–Beecham, Olga Gandelman, (unknown), (unknown), (unknown), Agnieszka Smolinska, (unknown), Billy Boyle, Marc P. van der Schee, Michael Allison, Rebecca C. Fitzgerald, Matthew Hoare, Victoria Snowdon	10
7	Trousseau's syndrome with non-bacterial thrombotic endocarditis (NBTE) in a patient with advanced pancreatic cancer 2023 ·Clinical Medicine ·(unknown), (unknown), (unknown), (unknown), Michael Allison	2
8	The Liver Retransplantation Risk Score: a prognostic model for survival after adult liver retransplantation 2021 ·Transplant International ·Isabel M.A. Brüggenwirth, Maureen J. M. Werner, René Adam, Wojciech G. Polak, Vincent Karam, Michael A. Heneghan, Arianeb Mehrabi, Jürgen Klempnauer, Andreas Paul, Darius F. Mirza, Johann Pratschke, Mauro Salizzoni, Daniel Cherqui, Michael Allison, Olivier Soubrane, Steven J. Staffa, David Zurakowski, Robert J. Porte, Vincent E. de Meijer	11
9	ATU-7 Incident acute kidney injury has a worse prognosis than baseline in severe alcoholic hepatitis 2021 ·(unknown), (unknown), Ewan Forrest, Michael Allison, Nikhil Vergis, (unknown)	1
10	Adipose Tissue-Liver Cross Talk in the Control of Whole-Body Metabolism: Implications in Nonalcoholic Fatty Liver Disease breakdown → 2020 ·Gastroenterology ·Vian Azzu, Michèle Vacca, Sam Virtue, Michael Allison, Antonio Vidal‐Puig	237
11	Lipid Remodeling in Hepatocyte Proliferation and Hepatocellular Carcinoma 2020 ·Hepatology ·Zoe Hall, Davide Chiarugi, Evelina Charidemou, Jack Leslie, Emma Scott, Luca Pellegrinet, Michael Allison, Gabriele Mocciaro, Quentin M. Anstee, Gérard I. Evan, Matthew Hoare, Antonio Vidal‐Puig, Fiona Oakley, Michèle Vacca, Julian L. Griffin	101
12	OTULIN protects the liver against cell death, inflammation, fibrosis, and cancer 2020 ·Cell Death and Differentiation ·Rune Busk Damgaard, Helen E. Jolin, Michael Allison, Susan Davies, Hannah Titheradge, Andrew N. J. McKenzie, David Komander	59
13	Baseline neutrophil‐to‐lymphocyte ratio predicts response to corticosteroids and is associated with infection and renal dysfunction in alcoholic hepatitis 2019 ·Alimentary Pharmacology & Therapeutics ·Ewan Forrest, (unknown), Rohit Sinha, Stephen R. Atkinson, Nikhil Vergis, Paul Richardson, Steven Masson, Stephen Ryder, Mark Thursz, Michael Allison, Andrew Fraser, Andrew Austin, Anne McCune, Ashwin Dhanda, Dev Katarey, Jonathan R. Potts, Sumita Verma, Richard Parker, Peter Hayes, (unknown)	48
14	Accuracy of FibroScan Controlled Attenuation Parameter and Liver Stiffness Measurement in Assessing Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease breakdown → 2019 ·Gastroenterology ·Peter Eddowes, M. Sasso, Michael Allison, Emmanuel Tsochatzis, Quentin M. Anstee, David Sheridan, Indra Neil Guha, Jeremy Cobbold, Jonathan J Deeks, Valérie Paradis, Pierre Bédossa, Philip N. Newsome	930
15	Care standards for non-alcoholic fatty liver disease in the United Kingdom 2016: a cross-sectional survey 2017 ·Frontline Gastroenterology ·David Sheridan, Guruprasad P. Aithal, William Alazawi, Michael Allison, Quentin M. Anstee, Jeremy Cobbold, Shahid A. Khan, Andrew Fowell, Stuart McPherson, Philip N. Newsome, Jude A. Oben, Jeremy Tomlinson, Emmanuel Tsochatzis	24
16	Lipid zonation and phospholipid remodeling in nonalcoholic fatty liver disease 2016 ·Hepatology ·Zoe Hall, Nicholas J. Bond, Tom Ashmore, Francis Sanders, Zsuzsanna Ament, Xinzhu Wang, Andrew J. Murray, Elena Bellafante, Sam Virtue, Antonio Vidal‐Puig, Michael Allison, Susan E. Davies, Albert Koulman, Michèle Vacca, Julian L. Griffin	151
17	Vacuolation in hepatocyte nuclei is a marker of senescence 2012 ·Journal of Clinical Pathology ·Aloysious Aravinthan, Suman Verma, Nick Coleman, Susan Davies, Michael Allison, Graeme Alexander	37
18	A Randomized Controlled Trial of Late Conversion From Calcineurin Inhibitor (CNI)-Based to Sirolimus-Based Immunosuppression in Liver Transplant Recipients with Impaired Renal Function 2007 ·Liver Transplantation ·Christopher J.E. Watson, Alexander Gimson, Graeme J.M. Alexander, Michael Allison, Paul Gibbs, J. Carson Smith, Christopher R. Palmer, J. Andrew Bradley	76
19	Sirolimus-Induced Pneumonitis Following Liver Transplantation 2007 ·Liver Transplantation ·Rebecca Roberts, Antonia C. Wells, Esther Unitt, Meryl Griffiths, A.D. Tasker, Michael Allison, J. Andrew Bradley, Christopher J.E. Watson	22
20	A single centre experience of liver disease in adults with cystic fibrosis 1995–2006 2007 ·Journal of Cystic Fibrosis ·Kathryn Nash, Michael Allison, Damian McKeon, David J. Lomas, (unknown), Diana Bilton, Graeme Alexander	48

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact